Accomplishments are evidenced by approved products and an advancing pipeline. Eight marketed and partnered products validate our technology and development approach.


Our collaborative approach to drug development is seen both internally and in successful partnerships. Partners include Novartis, Sandoz, Baxter and GSK.


Our formulation technologies and proprietary devices enable delivery directly to the lungs and underpin the company’s development pipeline.


Know-how and experience fuels innovation. Our experienced teams of scientists focus on developing innovative solutions in all areas of drug development.


Our drug development efforts are focused on airways – related diseases - a high unmet need and growing multi billion market.

Vectura is a respiratory product development Company. Enabled by our high-quality proprietary technologies, our experienced employees work hard to ensure we continue to be one of the leading names within our sector.

Our products

Our innovative and broad clinical pipeline combines mid- and late-stage programmes with earlier-stage opportunities addressing large and fast-growing market sectors

Annual Report

Annual Report and Accounts for Year Ended 31 March 2014


In focus

VR315 US development milestone

Chippenham, UK - 24 June 2014: Vectura Group plc (LSE: VEC; "Vectura" or the "Company") announces that it has triggered a milestone of $1.5 million associated with the development of VR315 in the US.

18 Nov 2014

Interim Results for the six months ending 30 September 2014